Press Releases
2024
Thomas Glanzmann becomes non-executive Chairman September 23 2024
Grifols Accelerates Performance in Q2 and Reaffirms Full Year Guidance July 30 2024
Grifols and Andorran government agree not to proceed with immunology research center July 25 2024
Grifols appoints Rahul Srinivasan as new Chief Financial Officer July 4 2024
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years July 1 2024
Grifols shareholders approve all agenda items at 2024 Annual General Meeting June 14 2024
Grifols succesfully closes the issuance of additional EUR 300 million secured notes June 4 2024
Grifols on track to meet full-year guidance and reduce debt May 14 2024
Grifols on track to close its strategic alliance with Haier in first half 2024 May 6 2024
Nacho Abia begins tenure as new Grifols CEO April 2 2024
Grifols shares CNMV statement March 25 2024
Grifols closes a record year and accelerates profitable growth for 2024 February 29 2024
Grifols’ Credit Rating Affirmed by S&P Global; Outlook Stable January 19 2024
2023
2022
2021
Grifols moves forward with its divestment plan by agreeing to sell VCN Biosciences December 14 2021
Grifols announces the commencement of an Asset sale Offer December 13 2021
Grifols is included on the Dow Jones Sustainability World Index November 15 2021
Grifols advances on the execution of its strategic plan November 11 2021
Grifols divests its hemostasis technology business for USD 25 million October 6 2021
Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest October 5 2021
Grifols earns its first Fitch corporate rating with a BB- and stable outlook September 27 2021
Grifols announces its investment in Biotest September 17 2021
Grifols announces a strategic investment from GIC of USD 1 billion June 30 2021
2020
Grifols revenues grow 10.5% to EUR 2,677 million driven by the Bioscience Division July 30 2020
Grifols acquires 10% stake in Bloodbuy, cloud-based marketplace for blood products July 23 2020
Grifols starts commercializing TAVLESSE® in Europe, diversifying its medicines portfolio July 9 2020
Grifols reinforces its liquidity position to EUR 1,700 million May 7 2020
Grifols and Shanghai RAAS close their strategic alliance in China March 27 2020
2019
Grifols presents its latest Alzheimer’s clinical trial data December 6 2019
Grifols introduces its first plasma protein-based biosurgery product December 4 2019
Grifols increases its revenues by 14.5% to EUR 3,738 million October 29 2019
Grifols presents additional encouraging Alzheimer’s trial results at AAIC July 16 2019
Grifols Announces Collaboration and License Agreement with Rigel Pharmaceuticals January 23 2019